# Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD

> **NCT06704321** · NA · RECRUITING · sponsor: **Valbiotis** · enrollment: 70 (estimated)

## Conditions studied

- Non-Alcoholic Fatty Liver Disease

## Interventions

- **DIETARY_SUPPLEMENT:** TOTUM-448
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT06704321
- **Lead sponsor:** Valbiotis
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-31
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2024-11-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06704321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06704321, "Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06704321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*